RSS Content

Zomedica Pharmaceuticals Corp. to Present at LD Micro NYC Summit and Cantor 2018 Global Healthcare Conference

ANN ARBOR, Mich., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced that it will present at the LD Micro NYC Summit on September 25 in New York, NY, and at the Cantor Global Healthcare Conference on October 2 in New York, NY.

Chief Financial Officer Shameze Rampertab, CPA, CA, will provide an overview of Zomedica’s business during his presentations and will be available to participate in one-on-one meetings with investors invited to attend each conference.

LD Micro NYC Summit

The LD Micro NYC Summit is an invite-only event. Interested parties should contact david@ldmicro.com for further information.

Cantor Global Healthcare Conference

Date: Tuesday, October 2, 2018
Time: 4:35 p.m. ET
Location: InterContinental New York Barclay Hotel, New York, NY

Webcast Information: Investors and other interested parties will be able to access a live webcast of the presentation by visiting Zomedica’s website at http://www.zomedica.com/investor-information/events-presentations/. A replay of the audio webcast and copies of the presentation will be accessible on the Zomedica website following the event.

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Investor Relations Contacts
Shameze Rampertab, CPA, CA
srampertab@zomedica.com
+1 647.283.3630

PCG Advisory Group
Kirin Smith, COO
ksmith@pcgadvisory.com
+1 646.863.6519
www.pcgadvisory.com

Media Contact
Andrea Eberle
aeberle@zomedica.com
+1 734.369.2555

zomedica-horizontal-tag.jpg

Zomedica Pharmaceuticals Corp.